Literature DB >> 22897767

A rapid and convenient method to enhance transgenic expression in target cells.

Chia-Hung Chen1, Yen-Ku Liu, Yu-Ling Lin, Huai-Yao Chuang, Wei-Tung Hsu, Yi-Han Chiu, Tian-Lu Cheng, Kuang-Wen Liao.   

Abstract

Gene therapy provides a novel strategy and a new hope for patients with cancer. Unfortunately, the specifics of the delivery systems or the promoters have not achieved the specified efficacy so far, and the perfection of either system will be extremely difficult. In this study, we introduce a simple concept that a combination of a partially specific delivery system and a partially specific promoter activity may achieve a more specific effect on transgenic expression in target cells. The first section describes tumor-related transcription factors that were assayed in tumors or rapidly proliferating cells to determine their activities. The activities of nuclear factor (NF)-κB, CREB, and HIF-1 were higher, and three copies of each response element were used to construct a transcription factor-based synthetic promoter (TSP). The results showed that the expression of the TSP was active and partially specific to cell types. As described in the second section, the multifunctional peptide RGD-4C-HA was designed to absorb polyethyleneimine (PEI) molecules, and this complex was targeted to integrin αvβ3 on B16F10 cells. The results indicated that RGD-4C-HA could associate with PEI to mediate specific targeting in vitro. Finally, the combination of the PEI-peptide complex and TSP could enhance the specifically transgenic expression in B16F10 cells. This strategy has been proven to work in vitro and might potentially be used for specific gene therapy in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22897767     DOI: 10.1080/10826068.2011.644013

Source DB:  PubMed          Journal:  Prep Biochem Biotechnol        ISSN: 1082-6068            Impact factor:   2.162


  1 in total

1.  Development of a computational promoter with highly efficient expression in tumors.

Authors:  Shu-Yi Ho; Bo-Hau Chang; Chen-Han Chung; Yu-Ling Lin; Cheng-Hsun Chuang; Pei-Jung Hsieh; Wei-Chih Huang; Nu-Man Tsai; Sheng-Chieh Huang; Yen-Ku Liu; Yu-Chih Lo; Kuang-Wen Liao
Journal:  BMC Cancer       Date:  2018-04-27       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.